INTRODUCTION
============

Atrial natriuretic factor/peptide (ANF/ANP) is produced and secreted in the specific granules of cardiac atrial myocytes, which participates in the control of extracellular fluid volume, electrolyte balance, and mean arterial pressure, thus, it plays a central role in the maintenance and regulation of cardiovascular homeostasis ([@B30]; [@B29]; [@B14]; [@B3]; [@B137], [@B138]). In addition to its natriuretic, diuretic, vasorelaxant, antimitogenic, antihypertrophic, and anti-inflammatory activities, ANP inhibits the release of renin from the kidneys, aldosterone from the adrenal glands, vasopressin from posterior pituitary, and progesterone from Leydig tumor (MA-10) cells, while stimulating the synthesis and release of testosterone from normal Leydig cells in the testes, progesterone from granulosa-leuteal cells, and luteinizing hormone from anterior pituitary gland ([@B69]; [@B14]; [@B99]; [@B137]). A number of studies have documented that ANP has always been found to increase the intracellular accumulation of cGMP, however, to decrease the levels of cAMP; Ca^2+^, and inositol triphosphate (IP~3~) in agonist hormone-treated cells and tissues ([@B192]; [@B140], [@B143]; [@B73], [@B75]; [@B137]; [@B184]). It has also been suggested that ANP decreases the cAMP levels by stimulating the cGMP-specific phosphodiesterases; however, in certain cells and tissue types, ANP did not decrease or change the cAMP concentrations. Several studies have indicated that ANP diminishes the Ca^2+^ signals probably by activating the Ca^2+^ extrusion processes by protein kinase-G (PKG) specifically in endothelial and vascular smooth muscle cells (VSMCs; [@B150]; [@B205]; [@B137]).

Among the natriuretic peptides (NPs) hormone family, ANP is the first described member, later, two other members of NP family; brain natriuretic peptide (BNP) and C-type natriuretic peptide (CNP) were identified and characterized, which also exhibited biochemical and structural properties similar to ANP; however, each prepro NP hormone is encoded from a separate gene ([@B155]; [@B99]). Although, all three NPs (ANP, BNP, and CNP) have highly homologous structure, they bind to specific NP receptors and elicit discrete biological and physiological functions ([@B14]). There have been three subtypes of NP receptors, namely; NP receptor-A, NP receptor-B, and NP peptide receptor-C (NPRA, NPRB, and NPRC, respectively), which were identified and characterized by molecular cloning ([@B144]; [@B47]). Interestingly, both ANP and BNP bind to NPRA, which produces the intracellular second messenger cGMP; however, CNP binds NPRB, which also generates cGMP, but all three NPs indiscriminately bind and activate NPRC, which lacks GC catalytic domain ([@B45]; [@B35]; [@B105]; [@B164]; [@B137]). The cellular, biochemical, and pharmacological aspects of NPs and their cognate receptors have revealed classic hallmark of physiological and pathophysiological functional significance, including; renal, cardiac, vascular, neuronal, and immunological aspects in health and disease ([@B137], [@B138]; [@B79]). It has been suggested that ANP suppresses Na^+^-reabsorption at the collecting duct of the kidneys, inhibits renin synthesis and release, and stimulates natriuresis and diuresis, thereby, lowers blood pressure and blood volume and maintains cardiovascular homeostasis ([@B29]; [@B14]; [@B99]; [@B137]). In the vasculature, ANP relaxes VSMCs thus causing the immediate vasorelaxant effect in the vascular bed ([@B99]; [@B137]).

The expression and activity of NPRA is regulated by various hormonal agents, including its ligand ANP ([@B132], [@B137]; [@B18]; [@B141]). The studies detailing the *Npr1* (coding for NPRA) gene-disruption in mice have revealed the functional significance of NPRA in the control of blood pressure and cardiovascular disease states ([@B125]; [@B166]; [@B60]; [@B189]; [@B79]; [@B138]; [@B198]). Mice lacking NPRA develop high blood pressure and severe cardiac hypertrophy, fibrosis, and disorders that are reminiscent of heart disease as seen in untreated human hypertensive patients ([@B190], [@B188]; [@B201]). The regulated expression of CNP is derived from endothelial cells, which targets NPRB on the adjacent smooth muscle cells ([@B174]). Thus, the principal role of CNP is considered as a direct vasodilator involved in the regulation of vascular tone through activation of GC-B/NPRB on smooth muscle cells in the vascular beds ([@B52]). The objective of this current review is to summarize and document the findings and discoveries with particular emphasis of cellular signaling and physiological and pathological significance of ANP/NPRA in relation to the increased production of intracellular second messenger cGMP and inhibition of the phosphoinositide (IP~3~) hydrolysis, Ca^2+^ release, and protein kinase C (PKC) activity in target cells.

HISTORICAL BACKGROUND
=====================

Thirty-three years ago, the pioneer discovery by de Bold and his coworkers established that atrial extracts contained natriuretic and diuretic activity which led to the isolation and nomenclature of ANF, usually referred to as ANP ([@B30]; [@B29]). Now, it is considered that ANP is primarily synthesized and secreted in the granules of heart atrium and BNP is largely synthesized in the heart ventricle and displays most variability in the primary structure. Although, the atrium is the primary site of synthesis for ANP, however, ventricle also produces ANP but at the levels of 100-fold to 1000-fold lower than that of the atrium, respectively ([@B81]). CNP was isolated from the porcine brain, however, is mostly present in the endothelial cells of the vasculature and is highly conserved among the mammalian species ([@B155]). The primary structure deduced from the cDNA synthesis, suggested that ANP is synthesized first as the 152-amino acid prepro-ANP molecule that contains sequences of active peptide in its carboxyl-terminal region ([@B107]). The biologically active ANP is released by proteolytic cleavage of pro-ANP molecule into predominantly 28-amino acid active (residues 99--126) and the 98 amino acid inactive (residues 1--98) molecules. The active form of ANP has a disulfide-bonded loop between cysteine 105 and 121, which seems to be essential for the biological activity ([@B14]). Initially, different lengths of sequences of ANP were identified and synthesized for the studies of structure-activity relationship, and it was suggested that the ring structure of ANP with a disulfide-bonded loop is essential for its biological activities ([@B155]). All three NPs contain highly conserved amino acid sequences with a 17-residues disulfide-bonded ring but deviate from each other in the N-terminal and C-terminal flanking amino acid sequences. Furthermore, the C-terminal sequence extending from the ring structure to Asn-Phe-Arg-Tyr is essential for the biological activity of ANP. The amino acid sequence of ANP is almost identical across the mammalian species, except at the position 10, which is substituted with isoleucine in rat, mouse, and rabbit, however, in human, dog, and bovine, ANPs have methionine in this position ([@B116]). Subsequently, BNP and CNP were both isolated and characterized from the porcine brain extracts ([@B171], [@B172]). BNP is predominantly synthesized and secreted from the heart ventricle ([@B146]). Similarly, CNP is predominantly localized in the central nervous system and endothelial cells and is considered as a non-circulatory peptide hormone ([@B174]).

NATRIURETIC PEPTIDES SYNTHESIS AND SECRETION
============================================

It has been suggested that the processing of preprohormone to prohormone molecule and the cleavage and secretion of biologically active mature 28-residue ANP molecule occurs predominantly in response to atrial distension ([@B29]; [@B14]). Usually, ANP concentration ranges from 50 to 100-fold higher than BNP; however, the expression of both ANP and BNP increases dramatically in the atrium and ventricle in the condition of cardiac disorders and heart failure ([@B119]). During the disease states, the ventricle becomes the primary site of synthesis and release for BNP. In congestive heart failure (CHF) patients, the concentrations of both ANP and BNP increase greater than the control values, however, the BNP concentration increases 10-fold to 50-fold higher than a comparative increases in the ANP levels ([@B119]). Those previous findings indicated that ANP and BNP elicit distinct physiological and pathophysiological effects, nevertheless, both hormones show similar hemodynamic responses, but BNP exerts a longer duration of action and causes enhanced natriuretic responses as compared with ANP ([@B199]; [@B127]). It has been suggested that the cardiac atrium expresses almost 50-fold to 100-fold or even higher levels of ANP mRNA as compared with extra -cardiac tissues ([@B48]). Interestingly, higher ventricular ANP levels have been found in the developing embryos and fetuses; however, both mRNA and peptide levels of ANP decline rapidly during the prenatal period ([@B16]). On the other hand, CNP does not seem to behave as a cardiac hormone and its concentration is extremely low in the circulation ([@B68]). It is believed that CNP is largely localized in the central nervous system and in the vascular endothelial cells ([@B124]; [@B174], [@B173]; [@B178]; [@B20]). Another class of NPs is the D-type natriuretic peptide (DNP) that represents an additional member in the NP hormone family and is largely present in the venom of the green mamba (*Dendroaspis angusticeps*) as a 38-amino acid peptide molecule ([@B162]; [@B101]). In addition, a 32-amino acid peptide termed as urodilatin (URO) is identical to C-terminal sequence of pro-ANP, which is largely present only in the urine ([@B160]). Initially, URO was purified from the human urine and is considered to be synthesized only in the kidneys ([@B158]). The immunohistochemical staining indicated that URO is largely present in the cortical tubules around the collecting ducts of the kidneys ([@B115]; [@B34]).

In the circulation, the half-life of BNP is greater than ANP, thus the evaluation of the diagnostic importance of the NPs have mostly favored BNP. The inactive N-terminal fragment of BNP (NT-proBNP) has even a greater half-life than the BNP. The plasma levels of both BNP and NT-proBNP are markedly elevated under the pathophysiological conditions of cardiac dysfunction, including diastolic dysfunction, CHF, and pulmonary embolism ([@B41]; [@B70]). The basal plasma levels of BNP vary from 5 to 50 pg/ml and NT-proBNP levels range from 10 to 150 pg/ml. An abnormal range is considered as 100 pg/ml for BNP and 125 pg/ml for NT-proBNP ([@B41]). Nevertheless, the secretion of both ANP and BNP from the ventricular myocytes increases proportionally in relation to the magnitude of cardiac dysfunction or heart failure condition ([@B200]). It has been suggested that BNP acts as an important prognostic indicator in the CHF patients, however, NT-proBNP is considered to be a stronger risk bio-indicator for cardiovascular events ([@B34]). Both BNP and NT-proBNP seem to provide an ideal tool to be utilized as blood tests to diagnose cardiac disorders in patients with high risk of heart failure, diabetes, chronic kidney disease, and coronary artery disease ([@B72]; [@B43]; [@B27]; [@B46]). The BNP level is increased to almost 200 pg/ml and NT-proBNP levels reaches to approximately 1200 pg/ml in patients with reduced creatinin clearance ([@B111]; [@B6]).

IDENTIFICATION AND CHARACTERIZATION OF RECEPTOR MEMBRANE GUANYLYL CYCLASE
=========================================================================

The previous studies using cross-linking and photoaffinity labeling procedures, have shown the existence of NP receptors with a wide range of molecular weight (M~r~) of the 60--180 kDa ([@B117]; [@B159]; [@B187]; [@B114]; [@B139]). Initially, NP receptors were identified with varying receptor density in different cells and tissue types (**Table [1](#T1){ref-type="table"}**). Subsequently, high affinity ANP binding sites were with GC activity were co-purified ([@B92]; [@B145]; [@B177]; [@B113]) On the basis of biological activity of different ANP analogs, NP receptors were classified and characterized as biologically active and clearance or silent receptors ([@B106]). Subsequently, three distinct subtypes of NP receptors were identified, which appeared to be specific to different cells and tissues ([@B143]). Based on the cellular, biochemical, and molecular biological studies, the NPs and their receptors are quite widespread in cell and tissue distributions ([@B98]; [@B143]; [@B14]; [@B108]; [@B99]; [@B137]). Molecular cloning and expression of cDNA from mouse, rate, and human, led to identify and characterize the primary structure of three distinct subtypes of NP receptors, which are currently designated as GC-A/NPRA, GC-B/NPRB, and NPRC ([@B45]; [@B22]; [@B161]; [@B144]; [@B36]). The general topological structures of GC-A/NPRA and GC-B/NPRB are consistent with at least four distinct domains, including extracellular ligand-binding domain, a single transmembrane spanning region, and intracellular protein kinase-like homology domain (protein-KHD), and GC catalytic domain. The transmembrane GC receptors contain a single cyclase catalytic site per protein molecule, however, based on the structural modeling data two polypeptide chains seem to be required to activate GC-A/NPRA ([@B194]; [@B94]; [@B186]). It has been indicated that the dimerization region of the receptor is located between the KHD and GC catalytic domain that has been predicted to form an amphipathic alpha helix structure. The GC-B/NPRB has the overall domain structure similar to that of GC-A/NPRA with binding affinity to CNP also produces the intracellular second messenger cGMP ([@B161]; [@B83]; [@B105]). NPRA is considered as the dominant subtype of the NP receptors found in peripheral organs and mediates most of the known functions of ANP and BNP hormones. Nevertheless, NPRB is localized mainly in the central nervous system and vascular tissues, which is thought to mediate the actions of CNP in the brain and also in the vascular bed. There are increasing numbers of other GC receptors; however, the specific ligands for these receptors are still being identified (**Table [2](#T2){ref-type="table"}**). The third member of the NP receptor family, NPRC, constitutes a large extracellular domain of 496-amino acids, a single transmembrane domain, and a very short 37-amino acid cytoplasmic tail that contains no sequence homology with any other known membrane receptor proteins and has been given the name by default as clearance receptor ([@B45]). The extracellular region of NPRC is approximately 30% identical to both GC-A/NPRA and GC-B/NPRB. Studies using the ligand receptor binding as a criterion, have shown that NPRC has much less stringent specificity and affinity for structural variants of ANP than does NPRA ([@B12]). The extracellular domain of NPRC possesses two pairs of cysteine residues along with one isolated cysteine near the transmembrane domain of the receptor. However, three potential signals for N-glycosylation and several serine and threonine for O-linked glycosylation sites are known to be present in the extracellular domain of NPRC ([@B45]). Previously, it has been suggested that NPRC may function as a clearance receptor to remove and clear NPs from the circulation, however, a number of studies have provided the evidence that NPRC plays roles in the biological actions of NPs ([@B3]; [@B110]; [@B204]). Thus, it is evident that the clearance name carries only by a default nomenclature to NPRC.

###### 

ANP-dependent binding parameters of GC-A/NPRA and intracellular accumulation of cGMP in different cell types.

  Cell type             ANP-dependent Intracellular cGMP (fold stimulation)   Ligand binding parameters of NPRA   
  --------------------- ----------------------------------------------------- ----------------------------------- ---------------
  Endothelial cells     15                                                    10--100 pM                          0.5 × 10^5^
  Granulosa cells       30                                                    10--100 pM                          0.5 × 10^5^
  Glomerulosa cells     50                                                    100--1 pM                           2 × 10^5^
  MA-10 cells           1,500                                                 100--1 nM                           1 × 10^6^
  MDCK cells            50                                                    10--100 pM                          0.5 × 10^5^
  N4TG1 cells           30                                                    1--100 pM                           0.5 × 10^5^
  Primary Ledig cells   60                                                    10--100 pM                          0\. 5 × 10^5^
  RTASM cells           10                                                    1--100 pM                           0.2 × 10^5^

HEK-293 cells, human embryonic Kidney-293 cells; kd, dissociation constant;

B

max

, receptor density; MA-10 cells, Leydig tumor cells; MDCK cells, Maiden-Darby kidney epithelial cells; N4TG1 cells, neuroblastoma cells; RTASM, rat thoracic aortic smooth muscle cells.

###### 

The distribution of natriuretic peptide receptors (NPRA, NPRB, and NPRC) and their gene-knockout phenotype.

  Receptor          Ligand                    Tissue-specific distribution                                                                                                                  Cell-specific distribution                                                                                                                                              Gene-knockout phenotype
  ----------------- ------------------------- --------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------
  NPRA *(Npr1)*     ANP/BNP                   Kidney, adrenal glands, brain, heart, liver, lung, olfactory, ovary, pituitary gland, placenta, testis, thymus, vascular beds, liver, ileum   Renal epithelial and mesangial cells, vascular smooth muscle cells, endothelial cells, Leydig cells, granulosa cells, fibroblasts, Neuroblastoma, LLCPk-1, MDCK cells   High blood pressure, hypertension, cardiac hypertrophy and fibrosis, inflammation, volume overload, reduced testosterone
  NPRB *(Npr2)*     CNP                       Adrenal glands, brain, cartilage, fibroblast, heart, lung, ovary, pituitary gland, placenta, testis, thymus, vascular beds                    Vascular smooth muscle cells, fibroblasts, chondrocytes                                                                                                                 Dwarfism, decreased adiposity, female sterility, seizures, vascular complication
  NPRC *(Npr3)*     ANP, BNP, CNP             Kidney, heart, brain liver, vascular bed, intestine                                                                                           Vascular smooth muscle cells, endothelial cells, mesangial cells, fibroblasts                                                                                           Bone deformation, skeletal over-growth, long bone overgrowth
  GC-D              Guanylyn/uroguanylyn      Olfactory neuroepithelium                                                                                                                                                                                                                                                                                             
  GC-E/(ROS-GC-1)   Ca^2+^-binding proteins   Retina, pineal gland                                                                                                                                                                                                                                                                                                  
  GC-F/(ROS-GC-2)   Ca^2+^-binding proteins   Retina, rod outer segment                                                                                                                                                                                                                                                                                             
  GC-G              Orphan                    Skeletal muscle, lung, intestine, and kidney                                                                                                                                                                                                                                                                          
  GC-Y-X1           Orphan                    Sensory neurons of *C*. *elegans*                                                                                                                                                                                                                                                                                     

NPRA, natriuretic peptide receptor-A;

Npr1

, coding for guanylyl cyclase/natriuretic peptide receptor-A; NPRB, natriuretic peptide receptor-B;

Npr2

, coding for guanylyl cyclase/natriuretic peptide receptor-B; NPRC, natriuretic peptide receptor-C;

Npr3

, coding for natriuretic peptide clearance receptor.

INTERNALIZATION AND DOWN-REGULATION OF GC-A/NPRA
================================================

The ligand-dependent internalization plays important role in the receptor down-regulation and signaling process. Down-regulation of GC-A/NPRA has been reported in a number of cells, including PC-12 cells containing endogenous receptors and transfected COS-7 and HEK-293 cells harboring recombinant receptors ([@B152]; [@B132]; [@B128], [@B141]). The carboxyl-terminal deletion mutation has shown that the specific sites in the GC catalytic domain and KHD of NPRA, play critical roles in the endocytosis and sequestration of the receptor ([@B128]). Previous studies have also indicated that after prolonged treatment of cultured cells with ANP, both the receptor density and GC activity were decreased with simultaneous reduction in mRNA of levels NPRA ([@B44]; [@B18], [@B17]; [@B65]). In addition, transforming growth factor-β1 (TGF-β1), angiotensin II (ANG II), and endothelin (ET-1) have also been shown to reduce mRNA levels of NPRA in various types of cultured cells ([@B44]; [@B21]; [@B49]; [@B7]). Those previous studies demonstrated that a decrease in mRNA levels of GC-A/NPRA correlated with the repressed transcriptional activity of the receptor. On the other hand, mRNA levels of NPRA are greatly increased by retinoic acid and histonedeacetylase inhibitor treatments ([@B88], [@B89],[@B90]). It has been suggested that NPRA exists in the phosphorylated state and the addition of ANP causes a decrease in the phosphate contents as well as reduction or desensitization of the ANP-dependent GC catalytic activity of NPRA [@B148]). The apparent mechanism of desensitization of NPRA is in contrast to many other cell-surface hormone receptors, which appear to be desensitized by phosphorylation ([@B168]; [@B64]; [@B97]; [@B170]). The initial findings have also indicated that ANP stimulates phosphorylation of NPRA ([@B8]; [@B130]; [@B38]; [@B96]). Later, it was suggested that cGMP-dependent PKG, a serine/threonine kinase is also phosphorylates NPRA ([@B1]).

The down-regulation of NPRC also seems to be associated with increased internalization of the ligand-receptor complexes involving receptor-mediated endocytosis and trafficking mechanisms of this receptor protein ([@B131]). The phenomenon of down-regulation of NPRC has been largely documented in cultured VSMCs, which predominantly contain a high density of NPRC ([@B122]; [@B58]; [@B63]; [@B131]; [@B2]). The metabolic processing of ANP involving NPRC has been reported by several investigators utilizing VSMCs ([@B59]; [@B121]; [@B120]; [@B123]; [@B131], [@B137]; [@B25]; [@B2]). It has been suggested that a population of the internalized NPRC also recycles back to the plasma membrane ([@B131]).

ACTIVATION OF GC-A/NPRA GENERATES INTRACELLULAR SECOND MESSENGER cGMP
=====================================================================

It is believed that cGMP is generated as a result of ANP binding to the extracellular domain of GC-A/NPRA, which probably allosterically regulates an increased activity of the receptor protein ([@B132], [@B137], [@B138]; [@B35]; [@B141]; [@B164]; [@B165]). The initial findings showed that ANP markedly increases cGMP in target tissues in a dose-related manner ([@B53]; [@B192]; [@B140]). Previous studies have also indicated that the binding of ANP to GC-A/NPRA by itself is probably not sufficient to stimulate GC catalytic activity and the production of cGMP, however, it requires ATP ([@B93]; [@B23]; [@B51]). Because the non-hydrolyzable analogs of ATP mimicked ANP effect, it was suggested that ATP acts directly by allosteric regulation of GC catalytic activity of NPRA. Both the ligand binding and the interaction of ATP with the KHD of the receptor increase the cGMP production without affecting the affinity for the substrate ([@B93]; [@B19]; [@B36]). Molecular cloning and overexpression of NPRA demonstrated that GC catalytic domain cannot be activated by ANP alone without ATP-binding to KHD region of the receptor ([@B23]; [@B95]; [@B195]). Further studies provided the evidence that ATP binding to KHD of NPRA is important for the effectors coupling of GC family of receptors ([@B51]; [@B164]).

Deletion of the KHD of GC-A/NPRA and GC-B/NPRB has been suggested that KHD represses the GC catalytic activity of these receptors ([@B22]). At the same time, another model was proposed indicating that KHD was not a repressor; however, ATP was required to activate the catalytic domain of NPRA ([@B51]; [@B164]). Both NPRA and NPRB contain a glycine-rich ATP binding motif within the KHD, which is known as glycine-rich consensus sequence ([@B36], [@B37]; [@B51]). The juxtamembrane hinge structure of NPRA undergoes a significant conformational change in response to ligand binding, and it may play an important role in transmembrane signaling process ([@B66]). The amino acid sequence near the transmembrane region is well conserved in GC-A/NPRA that contains several closely located proline residues and a pair of cysteine residues. The mutation of one of the proline in this region renders the receptor to bind the ligand but blocks GC catalytic activity ([@B66]). Similarly, in the juxtamembrane hinge region, the elimination of disulfide bond of cysteine residues resulted in constitutive activation of NPRA. Those previous findings suggested that juxtamembrane hinge region of NPRA may play a critical role in receptor activation and signal transduction mechanisms of GC-coupled receptors.

The glycosylation of the receptor seems to be essential for ligand binding activity of GC-A/NPRA ([@B104]; [@B42]). However, it has also been suggested that glycosylation may not be required for ligand binding of NPRA ([@B118]). The mutational analyses of N-linked glycosylation consensus sites in guanylyl cyclase-C (GC-C) have indicated that certain amino acid residues might be important for receptor stability ([@B56]). The glycosylation sites onto the GC-A/NPRA binding domain have been found to be scattered on the surface of the receptor with the exception of the hormone binding site and dimer interface ([@B185]). The glycosylation sites have been implicated to function in proper folding and stability of NPRA ([@B104]; [@B82]; [@B55]). Nevertheless, the glycosylation of the extracellular domain of NPRA can be considered of significant importance for receptor orientation and packaging on the cell surface similar to that of other plasma membrane receptor proteins ([@B196]). Nevertheless, it should be noted that there is no appreciable conservation of the precise position of the glycosylation sites within the members of GC-receptor family. Clearly, more studies are needed to confirm the functional roles of glycosylation in the transmembrane signaling processes of both GC-A/NPRA and GC-B/NPRB protein molecules.

ANP/NPRA SIGNALING INHIBITS PHOSPHOINOSITIDE HYDROLYSIS, Ca^2+^ RELEASE, AND PKC ACTIVITY
=========================================================================================

Previous studies have demonstrated that ANP significantly decreased the hydrolysis of phosphoinositide in murine Leydig tumor (MA-10) cells in a dose-dependent manner and the H-8, a specific inhibitor of PKG, reversed the inhibitory effect of ANP on the generation of inositol phosphates, supporting the involvement of PKG in this process ([@B74]). ANP has also been shown to inhibit both autophosphorylation and enzymatic activity of PKC in different cell systems ([@B130], [@B133],[@B134]; [@B91]). It is not yet clear if the ANP-dependent inhibitory effects on the phosphoinositide metabolism and PKC autophosphorylation and/or enzyme activity are exerted in a composite manner to negatively regulate the phosphoinositide, Ca^2+^, and PKC involving ANP/NPRA/cGMP/PKG cascade. It is also possible that the effect of ANP is transmitted to block the IP~3~ and Ca^2+^ signaling pathways independently in response to particular agonist stimulation. It has been suggested that potassium channels can be stimulated by ANP through the activation of PKGs, which require ATP and G-proteins ([@B193]). However, the possible involvements of potassium channels in the ANP-dependent inhibitory responses on the generation of inositol phosphates are not yet clearly understood. ANP has also been shown to stimulate the formation of inositol phosphates in cultured VSMCs, however, in the inner medullary collecting duct cells and smooth muscle tissues, ANP stimulated the production of inositol phosphates at lower dosages, and inhibited the formation of these metabolites at higher dosages, which increase intracellular generation of cGMP ([@B153]; [@B57]; [@B179]; [@B9]). Thus the heterogeneity of NP receptors and their diverse cellular distribution suggest that different mechanisms might be involved in the cellular action of ANP/NPRA/cGMP ([@B3]; [@B135], [@B136], [@B138]). It has also been shown that ANP inhibits the thrombin-induced synthesis and release of endothelin in cultured rat aortic endothelial cells by blocking the phosphoinositide breakdown ([@B39]).

In addition to the stimulatory effect of ANP on GC activity, it has also been shown to reduce adenylyl cyclase and phospholipase C activities, sodium influx, and Ca^2+^ concentrations ([@B14]; [@B3]; [@B137]). The increased production of cGMP in response to ANP correlates with the effects of dibutyryl-cGMP. The most compelling evidence supporting a role for cGMP effects was obtained with selective NPRA antagonists, A71915 and HS-121-1 in the kidneys ([@B191]; [@B156]). Those previous studies established that ANP effect is largely mediated by cGMP through the activation of GC-A/NPRA. In general, evidence suggests that biological activity of ANP/NPRA enhances the generation of the intracellular second messenger cGMP and decreases the levels of cAMP, Ca^2+^, and IP~3~ along with the antagonistic effects on PKC and mitogen-activated protein kinases (MAPKs) in target cells (**Figure [1](#F1){ref-type="fig"}**). ANP has been reported to induce cGMP-dependent acrosomal reaction in both capacitated and non-capacitated spermatozoa ([@B5]). Furthermore, the acrosome reaction was essentially equal in magnitude when induced with ANP or Ca^2+^ ionophore A23187. However, higher concentrations of ANP were required to induce acrosomal reaction in capacitated as compared with non-capacitated spermatozoa. Those previous findings indicated that ANP-induced human acrosomal reaction does not require physiological concentrations of extracellular Ca^2+^. Acrosomal reaction is known to involve various extracellular signals, including cAMP ([@B4]), cGMP ([@B85]), prostaglandins, Ca^2+^ and IP~3~ ([@B180]), and diacylglycerol ([@B13]).

![**Diagram represents the ligand specificity and physiological function(s) of GC-A/NPRA.** The ligand-binding to NPRA generates second messenger cGMP from the hydrolysis of GTP. An increased level of intracellular cGMP is produced, which activates three known cGMP effecter molecules namely; cGMP-dependent protein kinases (PKGs), cGMP-dependent phosphodiesterases (PDEs), and cGMP-dependent ion-gated channels (CNGs). The ANP/NPRA/cGMP signaling may antagonize a number of pathways including; intracellular formation of cAMP, Ca^2+^, IP~3;~ cytokine expression; and the activation of protein kinase C (PKC) and mitogen-activated protein kinases (MAPKs). The resulting signaling cascade can mimic the physiological responses of ANP/NPRA. LBD, ligand binding domain; TM transmembrane region; protein-KHD, protein kinase-like homology domain; and GCD, guanylyl cyclase catalytic domain; DD, dimerization domain of NPRA and NPRB. The ligand binding region, transmembrane domain, and small intracellular tail region of NPRC are indicated.](fnmol-07-00075-g001){#F1}

The established biochemical and cellular effects of ANP in the adrenal glomerulosa cells showed the activation of GC activity and K^+^ channel conductance; whereas T-type Ca^2+^ channels conductance and adenylyl cyclase activity are suppressed ([@B3]). The correlative evidence between ANP-induced cGMP accumulation and vasodilation has suggested the role of cGMP as the intracellular second messenger of dilator responses to ANP ([@B14]; [@B3]; [@B18]; [@B137]). ANP as well as cGMP analogs have been found to reduce the agonist-induced increases in cytosolic Ca^2+^ concentrations ([@B54]; [@B100]; [@B137]). It has been suggested that cGMP activates sarcolemmal Ca^2+^-ATPase, and this mechanism seems to be important in the ANP-induced decreases in cytosolic Ca^2+^ in VSMCs ([@B150]; [@B26]; [@B99]; [@B137]). Nevertheless, it is anticipated that the ultimate effect of ANP in VSMCs could be due to production of cGMP and the activation of PKG ([@B100]; [@B91]). However, more studies are needed to define the biochemical and molecular basis of NP actions in vasculature, including VSMCs and endothelial cells.

Initial studies from our laboratory and data published from others have also shown that both ANP and cGMP inhibited the autophosphorylation and enzymatic activity of PKC in the plasma membrane preparations of various target cells ([@B154]; [@B157]; [@B133],[@B134]; [@B91]). The activation of PKC triggers the agonist-dependent phosphorylation and activity of numerous cellular proteins causing alteration in many physiological and pathophysiological conditions, including hypertension, cardiac hypertrophy, ischemia, atherosclerosis, stroke, and neurological disorders ([@B103]; [@B183]; [@B86]; [@B91]). PKC is believed to be a multigene family, consisting of at least 12 isoenzymes that can be classified into classical, novel, and atypical forms ([@B62]; [@B31]). These PKC isoenzymes are multifunctional serine/threonine kinases that are largely activated by Ca^2+^/phospholipids and phorbol esters. However, some of these isoforms (e, δ, ή, and φ) do not require Ca^2+^, while other isoforms (ζ and 𝜀) do not require Ca^2+^ or phospholipid for PKC enzymatic activity. Previous studies have indicated that vasoconstrictive agents, including ANG II and ET-1, were able to activate several-fold PKC activity in cultured VSMCs, however, ANP potently antagonized the ANG II- and ET-1-stimulated PKC activity in the ANP/NPRA-dependent manner ([@B91]; [@B137]). The inhibitory effect of ANP was greatly amplified if cell were transfected with both PKC-α and NPRA cDNAs. The pretreatment of cells with NPRA antagonist A-71915, significantly blocked the production of cGMP as well as the inhibitory effect of ANP on PKC activity ([@B91]). The results of those previous studies provided strong evidence that ANP antagonizes the PKC activation involving ANP/NPRA/cGMP signaling cascade. Agonists that activate PKC also produce two distinct second messengers, IP3, which activates cytosolic free Ca^2+^ and diacylglycesol, which stimulates PKC activity ([@B10]; [@B40]; [@B151]; [@B91]). Our previous studies have suggested that ANP inhibits the formation of IP3 in a cGMP-dependent manner in the intact cells, suggesting that the inhibitory effect of ANP on PKC activity might be linked with its antagonistic action on IP~3~ formation, however, more studies are needed to support these observations in various ANP-responsive cell and tissues systems.

EFFECT OF NPRA ON THE INHIBITION OF MAPKs ACTIVITY AND CELL PROLIFERATION
=========================================================================

It has been shown that cGMP analogs mimicked the antiproliferative action of ANP, indicating that it exerts the antimitogenic effects largely through the intracellular second messenger cGMP ([@B100]; [@B67]; [@B129]; [@B163]). ANP has been shown to inhibit collagen synthesis in cardiac fibroblasts and also it inhibits hypertrophy of cardiac myocytes ([@B15]; [@B109]; [@B169]; [@B61]; [@B50]). Similarly, PKG has been shown to suppress extracellular matrix production in VSMCs ([@B33]). Both NPRA and NPRC, have been suggested to play a role in ANP-dependent antimitogenic responses ([@B149]; [@B67]; [@B129]; [@B163]; [@B182]). ANP has been shown to act as a growth suppressor in a variety of cell types including; kidney, heart, neurons, thymus, vasculature, and fibroblasts ([@B99]; [@B137]). Previous studies have demonstrated that ANP inhibits ANGII- and platelet-derived growth factor (PDGF) -dependent MAPK activity in different tissues and cell types ([@B175]; [@B149]; [@B129]; [@B163]; [@B182]). However, in astroglial cells, ANP was shown to inhibit extracellular-regulated MAPK (Erk1/2) activity through NPRC ([@B149]). In contrast, recent findings have indicated that des- (Cys^105^--Cys^121^) -ANP, a ligand selective to NPRC, did not inhibit basal or serum-stimulated MAPK, however, CNP, which acts through NPRB, potently inhibited MAPK activity in fibroblasts in a cGMP-dependent manner ([@B24]).

It has been postulated that cGMP-dependent signaling mechanisms of GC-A/NPRA are initiated probably at the level of gene transcription; however, the exact mechanism of this activation remains to be elucidated. A previous report also indicated that cGMP/PKG signaling was able to increase the MAPK activity in contractile rat VSMCs ([@B84]). However, the process by which cGMP/PKG leads to the activation of MAPKs is unclear. Similarly, cAMP- and PKG have also been shown to inhibit as well as to activate MAPKs pathways, depending on the cell types and culture conditions ([@B11]). However, the involvement of specific ANP receptor subtypes in the inhibitory effects of ANP on the agonist-stimulated MAPKs activity is controversial. Indeed, more studies are needed to establish the underlying mechanisms of the antiproliferative effect of ANP in target cells. ANP has also been shown to induce apoptosis in cultured VSMCs and in neonatal rat cardiac myocytes ([@B181]; [@B197]). The apoptotic effect of ANP was mimicked by 8-bromo-cGMP, a membrane-permeable analog of cGMP, and also by nitroprusside, an activator of soluble guanylyl cyclase. Furthermore, the effect of ANP was greatly potentiated by a cGMP-specific phosphodiesterase inhibitor zaprinast. It has been indicated that norepinephrine, a myocyte growth and proliferative effector molecule, inhibited ANP-induced apoptosis via activation of β-adrenergic receptor and elevation of cAMP ([@B197]). The existence of a complementary ANP-mediated mechanism to inhibit cell growth and proliferation is not anticipated. Nevertheless, the inhibition of cell proliferation is often accompanied by an increased probability of apoptosis, whereas, growth-promoting agents and agonist hormones tend to promote cell growth and proliferation. For instance, ANG II inhibits apoptosis, in contrast, ANP and nitric oxide, both potently inhibit cell growth and proliferation and induce apoptosis ([@B147]; [@B197]). It has been suggested that the anti-apoptotic molecule Bcl-2 homolog Mcl-1 might serve as an important target in ANP-induced apoptosis. Intriguing was the finding that the Bcl-2 homolog Mcl-1 was initially identified as a protein marker, which was up-regulated during the differentiation of the monocytoid cell line ML-1 cells ([@B87]; [@B76]; [@B197]).

GENE-TARGETING OF *Nppa* AND *Npr1*
===================================

Genetic-targeting strategies in mice have provided novel approaches to study the physiological responses corresponding to gene-dosage *in vivo* ([@B176]; [@B77]). Genetically modified mice carrying *Npr1* gene-disruption or gene-duplication have provided strong support for the physiological roles of NPs and their receptors in the intact animals ([@B71]; [@B102]; [@B78]; [@B125], [@B126]; [@B110]; [@B142]; [@B166], [@B167]; [@B60]; [@B189]; [@B28]; [@B201]). Numerous studies have examined the quantitative contributions and possible mechanisms mediating the responses of *Npr1* gene copies by determining the renal plasma flow (RPF), glomerular filtration rate (GFR), urine flow, and sodium excretion following blood volume expansion in *Npr1* homozygous null mutant (*Npr1*^-/^*^-^;* 0-copy), wild-type (*Npr1*^+/+^*;* 2-copy), and gene-duplicated (*Npr1*^++/++^*;* 4-copy) mice in a *Npr1* gene-dose-dependent manner ([@B167]). Although, the blood volume expansion stimulated the release of ANP in all three *Npr1* genotypes of mice, significant functional responses (RPF, GFR, and sodium excretion) occurred only in *Npr1^-/-^* and *Npr1*^++/++^ mice but not in *Npr1^-/-^* mice. These findings demonstrated that the ANP/NPRA axis is primarily responsible for mediating the renal hemodynamic and sodium excretory responses to intravascular blood volume expansion. ANP responses to volume expansion led to the significantly lesser excretion of Na^+^ and water in 0-copy null mutant mice and significantly greater excretory responses along with reduced tubular reabsorption in 4-copy mice as compared with 2-copy wild-type mice. Similarly, during the volume expansion, urinary cGMP concentration was significantly lower in null mutant mice and greater in gene-duplicated mice. Our previous findings have established that NPRA is a hallmark receptor, which plays a critical role in mediating the natriuresis, diuresis, and renal hemodynamic responses to acute blood volume expansion ([@B167]).

Genetic mouse models with disruption of both *Nppa* and *Npr1* genes have provided strong support for the role of this hormone-receptor system in the regulation of blood pressure, cardiac hypertrophy, and other physiological functions ([@B71]; [@B102]; [@B125], [@B126]; [@B112]; [@B142]; [@B166], [@B167]; [@B60]; [@B189]; [@B79]; [@B138]). Therefore, the genetic defects that reduce the activity of ANP and its receptor system can be considered as candidate contributors to essential hypertension and CHF ([@B71]; [@B142]; [@B203]; [@B80]; [@B60]; [@B167]; [@B189]). Interestingly, complete absence of NPRA causes hypertension in mice and leads to altered renin and ANG II levels, cardiac hypertrophy, and lethal vascular events similar to those seen in untreated human hypertensive patients ([@B125]; [@B166], [@B167]; [@B202]). In contrast, increased expression of *Npr1* reduces the blood pressures and inflammatory responses, protects heart, and increases the intracellular second messenger cGMP concentrations corresponding to the increasing number of *Npr1* gene copies ([@B126]; [@B142]; [@B167]; [@B190], [@B188]; [@B201]). Recent evidence also indicates that CNP and its receptor NPRB can play important role in regulating the cardiac hypertrophy and remodeling as a potential drug target for the treatment of cardiovascular diseases ([@B32]).

CONCLUSION
==========

The field of NPs has been advanced to examine the function and signaling mechanisms of their receptors and the role of second messenger cGMP in physiology and pathophysiology of hypertension, renal hemodynamics, cardiovascular functions, and neural plasticity. The development of gene-knockout and gene-duplication mouse models along with transgenic mice have provided a framework for understanding both the physiological and pathophysiological functions of NPs and their receptors in the intact animals *in vivo*. Although, a considerable progress has been made, the transmembrane signal transduction mechanisms of NPs and their receptors remain unresolved. Future investigations should include; the identification and characterization of cellular targets of intracellular second messenger cGMP produced by NPs, including cytosolic and nuclear proteins, role in gene transcription, cell growth and proliferation, apoptosis, and differentiation. A more vigorous studies of the crosstalk with other signaling mechanisms namely, PKC, MAPKs, cAMP, Ca^2+^, and IP~3~ needs to be pursued systematically. NPs are considered as circulating markers of CHF, however, their therapeutic potential for the treatment of cardiovascular diseases such as hypertension, renal insufficiency, cardiac hypertrophy, CHF, and stroke is still lacking. The ultimate goal of the investigations is this field is to fully appreciate the mechanisms of cGMP generation after ligand binding to GC-coupled receptors and the pathways leading to elicit cellular and physiological functions in relation to other signaling molecules with special emphasis to Ca^2+^, IP~3~, and cAMP levels. Identification of the discrete switch points in signal transmission of NPs and their cognate receptors that specify unique directional responses need to be vigorously pursued.

Conflict of Interest Statement
==============================

The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

I thank my wife Kamala Pandey for her generous help in the preparation of this manuscript. The research in the author's laboratory is supported by the grants from the National Institutes of Health (HL 57531 and HL 62147).

[^1]: Edited by: *Teresa Duda, Salus University, USA*

[^2]: Reviewed by: *Sandhya Srikant Visweswariah, Indian Institute of Science, India; Teresa Duda, Salus University, USA*

[^3]: This article was submitted to the journal Frontiers in Molecular Neuroscience.
